Clinical Trials
Catalent Biologics Completes Madison Facility Expansion to Double Clinical and Commercial Drug Substance Capacity
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced...
Clinical Trials
Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
Eli Lilly and Company and Incyte announced results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC)...
Clinical Trials
Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial
Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced the engagement of...
Clinical Trials
OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
OSE Immunotherapeutics announced that the Belgian Federal Agency for Medicines and Health Products (Agence Fédérale des Médicaments et des Produits de Santé - AFMPS) and...
Clinical Trials
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
Pfizer Inc. and BioNTech SE announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence...
Clinical Trials
Daiichi Sankyo begins phase 1 trial in Japan for nafamostat inhalation formulation to treat Covid-19
Daiichi Sankyo Company, Limited announced that it has initiated in Japan a first-in-human phase 1 trial for nafamostat inhalation formulation (DS-2319), which is being developed...
Clinical Trials
Humanigen Reports Positive Phase 3 Topline Results Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
Humanigen, Inc., a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.